Anomer Bio

Anomer Bio is a biotechnology company developing synthetic monosaccharides and small molecule drugs that target glycans, the sugars coating cell surfaces that influence immune responses and disease.

Its platform combines multi-omics data and machine learning to model how cells process sugars, enabling the design of orally delivered compounds that reprogram disease-driving glycan structures.

The company's pipeline spans immuno-oncology and rare glycan-related disorders. Anomer Bio operates from Stevenage Bioscience Catalyst, having previously traded as Glyconix.